OCUP Stock Price, Ocuphire Pharma, Inc. Quote, Chart

Market Summary

USD1.53-0.01

Market Closed

-0.65%

OCUP Alerts

2 major insider buys recently.

OCUP Stock Price

View Fullscreen

OCUP RSI Chart

OCUP Valuation

Market Cap

38.2M

Price/Earnings (Trailing)

-3.83

Price/Sales (Trailing)

2.01

EV/EBITDA

1.23

Price/Free Cashflow

-34.36

OCUP Price/Sales (Trailing)

OCUP Profitability

EBT Margin

-52.36%

Return on Equity

-20.01%

Return on Assets

-18.51%

Free Cashflow Yield

-2.91%

OCUP Fundamentals

OCUP Revenue

Revenue (TTM)

19.0M

Rev. Growth (Yr)

798.04%

Rev. Growth (Qtr)

224.85%

OCUP Earnings

Earnings (TTM)

-10.0M

Earnings Growth (Yr)

-114.13%

Earnings Growth (Qtr)

-186.23%

Breaking Down OCUP Revenue

Last 7 days

-11.5%

Last 30 days

-24.1%

Last 90 days

-43.0%

Trailing 12 Months

-71.2%

How does OCUP drawdown profile look like?

OCUP Financial Health

Current Ratio

13.35

OCUP Investor Care

Shares Dilution (1Y)

8.80%

Diluted EPS (TTM)

-0.47

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	34.6M	29.4M	24.2M	19.0M
2022	0	0	0	39.9M
2021	0	1.3M	589.0K	20.2M
2020	0	0	0	0
2019	0	0	0	0
2018	0	0	0	0
2017	0	0	0	0
2016	0	0	0	0
2015	0	0	0	0
2014	0	0	0	0
2013	0	0	0	0
2012	0	0	0	0
2011	0	0	0	0
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Ocuphire Pharma, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 11, 2024	pepose jay	acquired	-	-	32,000	-
Mar 21, 2024	schachle joseph k	bought	4,100	2.05	2,000	chief operating officer
Mar 21, 2024	jhaveri nirav s.	bought	21,000	2.1	10,000	chief financial officer
Mar 18, 2024	magrath george	bought	49,050	1.962	25,000	chief executive officer
Feb 12, 2024	jhaveri nirav s.	acquired	-	-	140,000	chief financial officer
Feb 12, 2024	jayagopal ashwath	acquired	-	-	75,000	chief scientific & dev. ofc.
Jan 18, 2024	zaremba rabourn amy	acquired	-	-	40,000	svp of finance
Jan 18, 2024	hoffmann bernhard	acquired	-	-	20,000	svp of corp. dev.
Jan 10, 2024	patel ronil a.	sold (taxes)	-4,185	3.265	-1,282	chief business officer
Jan 10, 2024	zaremba rabourn amy	sold (taxes)	-12,896	3.265	-3,950	svp of finance

Which funds bought or sold OCUP recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	RICE HALL JAMES & ASSOCIATES, LLC	reduced	-48.93	-1,134,160	586,890	0.03%
Apr 23, 2024	Summit Trail Advisors, LLC	new	-	21,195	21,195	-%
Apr 16, 2024	TOTH FINANCIAL ADVISORY CORP	unchanged	-	-1,001	2,013	-%
Apr 11, 2024	OPTIMUM INVESTMENT ADVISORS	unchanged	-	-1,000	2,010	-%
Apr 05, 2024	NBC SECURITIES, INC.	unchanged	-	-	1,000	-%
Apr 04, 2024	TRUST CO OF TOLEDO NA /OH/	unchanged	-	-30,963	62,236	0.01%
Mar 11, 2024	VANGUARD GROUP INC	added	8.03	-84,319	2,792,680	-%
Mar 08, 2024	ICA Group Wealth Management, LLC	new	-	90.00	90.00	-%
Feb 16, 2024	GSA CAPITAL PARTNERS LLP	sold off	-100	-46,000	-	-%
Feb 15, 2024	JANE STREET GROUP, LLC	new	-	104,420	104,420	-%

Are Funds Buying or Selling OCUP?

Are funds buying OCUP calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own OCUP

No. of Funds

OCUP Alerts

2 major insider buys recently.

Unveiling Ocuphire Pharma, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2023	sooch mina	5.5%	1,187,352	SC 13G/A
May 17, 2022	richmond brothers, inc.	5.84%	1,123,539	SC 13G
Feb 14, 2022	altium capital management lp	4.99%	384,615	SC 13G/A
Feb 14, 2022	sooch mina	6.7%	1,286,262	SC 13G/A
Jan 18, 2022	empery asset management, lp	4.99%	3,063,498	SC 13G/A

Recent SEC filings of Ocuphire Pharma, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 19, 2024	PRE 14A	PRE 14A
Apr 17, 2024	8-K	Current Report
Apr 15, 2024	4	Insider Trading
Mar 27, 2024	8-K	Current Report
Mar 25, 2024	4	Insider Trading
Mar 25, 2024	4	Insider Trading
Mar 20, 2024	4	Insider Trading
Mar 08, 2024	8-K	Current Report
Mar 08, 2024	10-K	Annual Report
Feb 16, 2024	8-K	Current Report

Peers (Alternatives to Ocuphire Pharma, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	2.33%	-21.90%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.4B	1.8B	-0.30%	-28.67%	-41.79	10.06	76.23%	61.08%
BMRN	17.4B	2.4B	8.14%	-4.26%	103.61	7.18	15.42%	18.43%
INCY	11.6B	3.7B	-9.39%	-31.39%	19.4	3.14	8.87%	75.42%
MID-CAP
APLS	5.9B	396.6M	-12.04%	-45.12%	-11.11	14.81	425.83%	18.94%
BBIO	4.5B	-	-13.93%	67.39%	-6.85	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-9.40%	-0.33%	-14.47	12.79	440.80%	-27.84%
ARWR	2.9B	240.7M	-12.61%	-20.79%	-9.93	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-6.74%	-16.88%	-45.01	3.8	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-6.36%	-10.84%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-10.64%	-48.02%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	8.01%	271.09%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-10.76%	0.48%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	76.15%	62.71%	-0.24	2.14	-13.45%	66.37%

Ocuphire Pharma, Inc. News

Latest updates

Ocuphire Pharma, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2021Q4	2021Q3	2021Q2	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4	2018Q3	2018Q2	2018Q1	2017Q4	2017Q3
Revenue	-85.8%	1,691,000	11,935,000	3,674,000	1,749,000	1,329,000	909,000	489,000	100,000	-	-	1,150,000	-	-	-	-	-	-	-	-	-	-
Operating Expenses	28.3%	7,120,000	5,549,000	9,063,000	7,880,000	5,640,000	6,150,000	4,721,000	7,237,000	1,948,000	1,262,000	2,735,000	-5,013,793	2,280,624	2,988,417	3,937,752	4,966,470	4,683,907	5,001,441	5,885,855	-	-
S&GA Expenses	59.6%	3,279,000	2,055,000	4,340,000	2,285,000	2,054,000	1,414,000	1,595,000	3,408,000	565,000	551,000	391,000	-2,364,744	1,149,206	1,340,016	1,695,523	2,236,493	1,795,952	1,568,848	1,827,322	-	-
R&D Expenses	-	-	-	-	-	-	-	-	-	149,594	231,607	456,790	454,728	1,131,418	1,648,401	2,242,229	2,729,977	2,887,955	3,432,593	4,058,533	-	-
EBITDA Margin	-143.6%	-0.52	1.20	0.64	0.55	0.46	-2.80	-108	-48.38	-	-	-	-	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	2,000	-	-	179,000	689,000	554,000	-	-	-	-	-	-	-	-	-	-
Income Taxes	-114.3%	-2,000	14,000	-	-	315,000	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-186.0%	-4,797,000	5,575,000	-4,961,000	-5,791,000	34,256,000	-6,313,000	-4,230,000	-7,136,000	-1,248,000	-1,604,000	-3,088,000	-	-	-	-	-	-	-	-	-	-
EBT Margin	-143.7%	-0.52	1.20	0.64	0.55	0.46	-2.80	-117	-52.86	-	-	-	-	-	-	-	-	-	-	-	-	-
Net Income	-186.2%	-4,795,000	5,561,000	-4,961,000	-5,791,000	33,941,000	-6,313,000	-4,230,000	-7,136,000	-1,248,000	-1,604,000	-3,088,000	597,510	-1,959,230	-2,464,284	-2,342,996	-3,116,570	-5,338,819	-3,838,268	-2,074,873	-	-
Net Income Margin	-144.2%	-0.52	1.19	0.63	0.54	0.45	-2.80	-117	-52.86	-	-	-	-	-	-	-	-	-	-	-	-	-
Free Cashflow	251.4%	4,548,000	-3,003,000	989,000	-3,646,000	28,791,000	-5,646,000	-3,584,000	-4,328,000	-	-	-	-	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-0.4%	54.00	54.00	43.00	45.00	49.00	15.00	18.00	20.00	26.00	23.00	25.00	12.00	18.00	9.00	10.00	12.00	2.00	15.00	18.00	19.00	16.00
Current Assets	-0.4%	54.00	54.00	43.00	45.00	49.00	15.00	18.00	20.00	26.00	23.00	25.00	12.00	18.00	9.00	10.00	11.00	2.00	15.00	17.00	19.00	16.00
Cash Equivalents	19.1%	51.00	42.00	40.00	39.00	43.00	14.00	17.00	19.00	25.00	22.00	24.00	11.00	16.00	1.00	1.00	1.00	2.00	8.00	7.00	6.00	0.00
Net PPE	-100.0%	-	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Liabilities	3.4%	4.00	4.00	6.00	4.00	3.00	3.00	3.00	3.00	4.00	3.00	3.00	2.00	31.00	3.00	3.00	2.00	9.00	3.00	4.00	3.00	5.00
Current Liabilities	3.4%	4.00	4.00	6.00	4.00	3.00	3.00	3.00	3.00	4.00	3.00	3.00	2.00	3.00	3.00	3.00	2.00	9.00	3.00	4.00	3.00	3.00
Short Term Borrowings	-	-	-	-	-	-	-	-	0.00	1.00	-	-	-	-	-	-	-	-	-	-	-	-
Shareholder's Equity	-0.7%	50.00	50.00	38.00	41.00	46.00	12.00	15.00	17.00	22.00	21.00	23.00	10.00	-	6.00	7.00	9.00	10.00	12.00	14.00	16.00	11.00
Retained Earnings	-6.3%	-81.47	-76.67	-82.23	-77.27	-71.48	-105	-100	-95.96	-89.37	-83.05	-78.82	-71.69	-32.67	-167	-166	-163	-8.05	-161	-159	-157	-154
Additional Paid-In Capital	3.5%	131	127	120	119	118	117	115	113	112	104	101	82.00	19.00	174	173	173	0.00	173	173	173	165
Shares Outstanding	6.0%	24.00	23.00	21.00	21.00	21.00	20.00	19.00	19.00	19.00	14.00	14.00	11.00	11.00	-	-	-	-	-	-	-	-
Float	-	-	-	89.00	-	-	-	37.00	-	-	-	84.00	-	-	-	11.00	-	-	-	21.00	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	251.4%	4,548	-3,003	989	-3,646	28,791	-4,498	-3,809	-6,170	-5,646	-3,584	-4,328	-5,812	-4,358	-1,056	-651	-732	4,972	-2,377	-1,806	-4,380	-4,620
Share Based Compensation	24.1%	711	573	1,422	804	424	493	445	445	479	478	463	494	513	616	316	61.00	-71.35	91.00	128	161	383
Cashflow From Investing	-	-	-	-	-	-	-	-	-	-100	-	-	-	539	-	-	-	-123	3,000	2,994	-5,895	2,000
Cashflow From Financing	-33.0%	3,603	5,376	-	-	-12.00	1,328	1,588	882	8,030	1,600	17,965	10.00	19,496	924	252	448	-2,949	-	-	7,654	-

OCUP Income Statement

2023-12-31

Statements of Comprehensive (Loss) Income - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Statements of Comprehensive (Loss) Income [Abstract]
License and collaborations revenue	$ 19,049	$ 39,850
Operating expenses:
General and administrative	11,959	7,269
Research and development	17,653	14,355
Total operating expenses	29,612	21,624
(Loss) income from operations	(10,563)	18,226
Financing costs (Note 8)	(1,328)	0
Interest expense (Note 4)	0	(9)
Fair value change in derivative liabilities	80	0
Other income (expense), net	1,837	(14)
(Loss) income before income taxes	(9,974)	18,203
Provision for income taxes	(12)	(315)
Net (loss) income	(9,986)	17,888
Other comprehensive (loss) income, net of tax	0	0
Comprehensive (loss) income	$ (9,986)	$ 17,888
Net (loss) income per share (Note 10):
Basic (in dollars per share)	$ (0.46)	$ 0.9
Diluted (in dollars per share)	$ (0.46)	$ 0.87
Number of shares used in per share calculations:
Basic (in shares)	21,589,821	19,931,080
Diluted (in shares)	21,589,821	20,597,212

OCUP Balance Sheet

2023-12-31

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 50,501	$ 42,634
Accounts receivable	926	1,298
Contract assets and unbilled receivables (Note 9)	1,407	3,552
Prepaids and other current assets	1,099	1,453
Short-term investments	15	49
Total current assets	53,948	48,986
Property and equipment, net	0	6
Total assets	53,948	48,992
Current liabilities:
Accounts payable	2,153	1,069
Accrued expenses	1,815	1,684
Derivative liability	74	0
Total current liabilities	4,042	2,753
Total liabilities	4,042	2,753
Commitments and contingencies (Note 3 and Note 7)
Stockholders' equity:
Preferred stock, par value $0.0001; 10,000,000 shares authorized as of December 31, 2023 and 2022; no shares issued and outstanding at December 31, 2023 and 2022.	0	0
Common stock, par value $0.0001; 75,000,000 shares authorized as of December 31, 2023 and 2022; 23,977,491 and 20,861,315 shares issued and outstanding at December 31, 2023 and 2022, respectively.	2	2
Additional paid-in capital	131,370	117,717
Accumulated deficit	(81,466)	(71,480)
Total stockholders' equity	49,906	46,239
Total liabilities and stockholders' equity	$ 53,948	$ 48,992

About Ocuphire Pharma, Inc.

Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate for dim light or night vision disturbances; and for pharmacologically induced mydriasis and presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. The company is headquartered in Farmington Hills, Michigan.

CEO	Mr. Richard J. Rodgers M.B.A.
WEBSITE	ocuphire.com
INDUSTRY	Biotechnology
EMPLOYEES	9

Ocuphire Pharma, Inc. Frequently Asked Questions

What is the ticker symbol for Ocuphire Pharma, Inc.? What does OCUP stand for in stocks?

OCUP is the stock ticker symbol of Ocuphire Pharma, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Ocuphire Pharma, Inc. (OCUP)?

As of Tue Apr 23 2024, market cap of Ocuphire Pharma, Inc. is 38.21 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of OCUP stock?

You can check OCUP's fair value in chart for subscribers.

What is the fair value of OCUP stock?

You can check OCUP's fair value in chart for subscribers. The fair value of Ocuphire Pharma, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Ocuphire Pharma, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for OCUP so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Ocuphire Pharma, Inc. a good stock to buy?

The fair value guage provides a quick view whether OCUP is over valued or under valued. Whether Ocuphire Pharma, Inc. is cheap or expensive depends on the assumptions which impact Ocuphire Pharma, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OCUP.

What is Ocuphire Pharma, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, OCUP's PE ratio (Price to Earnings) is -3.83 and Price to Sales (PS) ratio is 2.01. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OCUP PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Ocuphire Pharma, Inc.'s stock?

In the past 10 years, Ocuphire Pharma, Inc. has provided -0.438 (multiply by 100 for percentage) rate of return.